What's Going On With Aardvark Therapeutics Stock On Wednesday?

Core Viewpoint - Aardvark Therapeutics Inc. has voluntarily paused its Phase 3 HERO trial for Prader-Willi Syndrome due to safety concerns, leading to a significant drop in stock price by almost 61% [1][2]. Group 1: Trial Update - The company will not release topline data from the HERO trial as previously expected in Q3 2026 due to reversible cardiac observations at higher than target therapeutic doses [2]. - The CEO emphasized the commitment to patient safety and the importance of evaluating the signals seen at elevated doses of ARD-101, while planning to collaborate closely with the FDA and the Prader-Willi Syndrome community [3]. Group 2: Stock Performance - The stock is trading 1.5% below its 20-day simple moving average (SMA) and 2.3% below its 100-day SMA, indicating a bearish trend [4]. - Shares have decreased approximately 73% over the past 12 months and are closer to their 52-week lows than highs [4]. - The RSI is at 50.00, indicating neutral territory, while the MACD is at -0.05, suggesting bearish pressure on the stock [5]. Group 3: Analyst Consensus - The stock carries a Buy Rating with an average price target of $21.89, although recent analyst actions have lowered targets [6]. - Key resistance is identified at $5.00 and key support at $4.50 [6].